FI51587C - Menetelmä terapeuttisesti vaikuttavien sulfamyyli-m-aminobentsoehappoj en valmistamiseksi. - Google Patents

Menetelmä terapeuttisesti vaikuttavien sulfamyyli-m-aminobentsoehappoj en valmistamiseksi.

Info

Publication number
FI51587C
FI51587C FI693661A FI366169A FI51587C FI 51587 C FI51587 C FI 51587C FI 693661 A FI693661 A FI 693661A FI 366169 A FI366169 A FI 366169A FI 51587 C FI51587 C FI 51587C
Authority
FI
Finland
Prior art keywords
sulfamyl
preparation
therapeutic action
aminobenzoic acids
aminobenzoic
Prior art date
Application number
FI693661A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI51587B (nl
Inventor
Peter Werner Feit
Original Assignee
Leo Pharm Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB38038/69A external-priority patent/GB1249490A/en
Application filed by Leo Pharm Prod Ltd filed Critical Leo Pharm Prod Ltd
Publication of FI51587B publication Critical patent/FI51587B/fi
Application granted granted Critical
Publication of FI51587C publication Critical patent/FI51587C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
FI693661A 1968-12-24 1969-12-17 Menetelmä terapeuttisesti vaikuttavien sulfamyyli-m-aminobentsoehappoj en valmistamiseksi. FI51587C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB38038/69A GB1249490A (en) 1968-12-24 1968-12-24 New sulphamyl-benzoic acid derivatives
GB3089869 1969-06-18
US84593969A 1969-07-24 1969-07-24
GB3803869 1969-07-29

Publications (2)

Publication Number Publication Date
FI51587B FI51587B (nl) 1976-11-01
FI51587C true FI51587C (fi) 1977-02-10

Family

ID=27448796

Family Applications (1)

Application Number Title Priority Date Filing Date
FI693661A FI51587C (fi) 1968-12-24 1969-12-17 Menetelmä terapeuttisesti vaikuttavien sulfamyyli-m-aminobentsoehappoj en valmistamiseksi.

Country Status (14)

Country Link
JP (2) JPS5420483B1 (nl)
BE (1) BE743744A (nl)
CH (1) CH532559A (nl)
DE (2) DE1964503A1 (nl)
DK (1) DK134548B (nl)
FI (1) FI51587C (nl)
FR (1) FR2027043B1 (nl)
IE (1) IE33874B1 (nl)
IS (1) IS985B6 (nl)
IT (1) IT1143801B (nl)
NL (1) NL154727B (nl)
NO (1) NO132234C (nl)
SE (1) SE380013B (nl)
YU (1) YU34983B (nl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647873A (en) * 1970-02-03 1972-03-07 Merck & Co Inc Nuclear sulfonyl substituted n-acyl-benzenesulfonamides
AR206507A1 (es) * 1972-10-13 1976-07-30 Ciba Geigy Ag Procedimiento para la obtencion de nuevos 4-eteres de acidos 3-amino-5-sulfamoilbenzoicos
DE2419970C3 (de) * 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
CA1135705A (en) * 1978-07-20 1982-11-16 Jens-Uwe Bliesener N-arylsulfonylpyrroles, their preparation, and therapeutic agents containing these compounds
DE3941703C2 (de) * 1989-12-18 2002-11-07 Sanol Arznei Schwarz Gmbh Bumetanid enthaltende pharmazeutische Zubereitung

Also Published As

Publication number Publication date
DE1964503A1 (de) 1970-07-09
FI51587B (nl) 1976-11-01
JPS5420483B1 (nl) 1979-07-23
DE1964504B2 (de) 1977-07-07
IT1143801B (it) 1986-10-22
IE33874L (en) 1970-06-24
NO132234B (nl) 1975-06-30
DK134548C (nl) 1977-05-02
IS1894A7 (is) 1971-06-25
IS985B6 (is) 1978-02-22
FR2027043B1 (nl) 1978-08-18
SE380013B (nl) 1975-10-27
YU319069A (en) 1979-12-31
JPS5024299B1 (nl) 1975-08-14
CH532559A (de) 1973-01-15
IE33874B1 (en) 1974-11-27
NL154727B (nl) 1977-10-17
DE1964504C3 (de) 1978-03-02
DK134548B (da) 1976-11-29
DE1964504A1 (de) 1970-07-09
NO132234C (nl) 1975-10-08
YU34983B (en) 1980-06-30
FR2027043A1 (nl) 1970-09-25
NL6919391A (nl) 1970-06-26
BE743744A (nl) 1970-06-24

Similar Documents

Publication Publication Date Title
FI49035C (fi) Menetelmä terapeuttisesti käytettävän 2-bromi-alfa-ergokryptiinin valm istamiseksi.
FI50059C (fi) Menetelmä hidasvaikutteisten tablettien kaltaisten annostusyksikköjen valmistamiseksi.
FI48590C (fi) Menetelmä terapeuttisesti käytettävien atsaspiroalkaanidioniyhdisteide n valmistamiseksi.
FI51347C (fi) Menetelmä 1-substituoitujen-3- ja -4-aroyylipiperidiinien valmistamise ksi.
FI48062C (fi) Menetelmä ksylitolin valmistamiseksi
FI50334C (fi) Menetelmä 1-hydroksi-2pyridonien valmistamiseksi.
FI50409C (fi) Menetelmä pyridiini-karboksyylihappojen valmistamiseksi
FI49512C (fi) Menetelmä uusien terapeuttisesti aktiivisten s-triatsinyylipiperatsiin ijohdannaisten valmistamiseksi.
FI50410C (fi) Menetelmä tulehdusta estävien substituoitujen aminopyriinien valmistam iseksi
FI48463C (fi) Menetelmä veren sokerpitoisuutta alentavien bentsolisulfonyyli-virtsa- aineiden valmistamiseksi.
FI51587C (fi) Menetelmä terapeuttisesti vaikuttavien sulfamyyli-m-aminobentsoehappoj en valmistamiseksi.
FI47575C (fi) Analogiamenetelmä evomonosidi-johdannaisten valmistamiseksi.
FI49407C (fi) Menetelmä kokkidiostaattisen vaikutuksen omaavien kinoliinikarbonihapp oestereiden valmistamiseksi.
FI45963C (fi) Menetelmä veren sokeripitoisuutta alentavien bentseenisulfonyylivirtsa -aineiden valmistamiseksi.
FI50407C (fi) Menetelmä trikloorimonosilaanien valmistamiseksi
FI45964C (fi) Menetelmä veren sokeripitoisuutta alentavien bentsolisulfonyylivirtsa- aineiden valmistamiseksi.
FI46727C (fi) Menetelmä pyridatsolijohdannaisten valmistamiseksi.
FI47578C (fi) Tapa valmistaa sepelvaltimoita laajentavan vaikutuksen omaavia 2,4,7-t riamino-6-fenyyli-pteridiinejä.
FI52577C (fi) Menetelmä terapeuttisesti käytettävien fenatsiinijohdannaisten valmist amiseksi.
FI47189C (fi) Tapa valmistaa terapeuttisesti vaikuttavia d-lysergiinihappo-N-fenyyli piperatsideja.
FI47350C (fi) Tapa valmistaa 17alfa-propadienyyli-steroideja.
FI47358C (fi) Menetelmä terapeuttisesti käytettävän 4&#39;-demetyyli-epipodofyllotoksiin i-beta-D-glukosidin valmistamiseksi.
FI51814C (fi) Menetelmä alfa-karboksibentsyylipenisiliinin kielteisen alkalimetallis uolojen valmistamiseksi.
FI46155C (fi) Menetelmä veren sokeripitoisuutta alentavien bentseenisulfonyylivirtsa -aineiden valmistamiseksi.
FI46722C (fi) Menetelmä 1alfa-hydroksi-18-metyyli-5alfa-H-androstaanijohdannaisten v almistamiseksi.